RVRohollah Vahabpour

Rohollah Vahabpour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rohollah Vahabpour has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Parvaneh Movahhed

    Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Ali Anjam Najmedini

    Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Ali Anjam-Najmedini

    Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Alireza Kazemi

    Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Atieh Pourbagheri-Sigaroodi

    Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Ava Safaroghli-Azar

    Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication

Latest Publications

  • Open Access

    Assessment of the Effect of Overexpression of Death-Associated Protein Kinases 3 Using PEGFPN1 on Gastric Adenocarcinoma Cell Line (MKN45)

    by Parvaneh Movahhed, Atieh Pourbagheri-Sigaroodi, Ali Anjam-Najmedini, Ruhollah Vahabpour, Faranak Kazerouni

    Background: Gastric cancer (GC) is one of the most common malignancies worldwide. An in-depth understanding of the molecular mechanisms that underlies tumor GC will lead to breakthroughs in the targeted treatment of GC. Based on multiple lines of evidence, death-associated protein kinase 3 (DAPK3) regulates both programmed cell death including apoptosis and autophagy. The widespread experimental evidence raises the possibility of using DAPK-based gene therapy strategies. Objectives: The aim of this study was to investigate the effect of overexpression of DAPK3 using the PEGFPN1 vector on the gastric adenocarcinoma cell line (MKN45). Methods: The MKN45 cell lines were cultured in a DMEM culture medium and, then, the recombinant vector PEGFPN1-DAPK3 was transfected into the cells by lipofectamine 2000. The effects of the overexpression of the DAPK3 gene on MKN45 cells were evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), flow cytometry, and real-time quantitative reverse transcription PCR (qRT-PCR) techniques. Results: Our findings indicated that overexpression of DAPK3 in MKN45 cells not only affects the expression of apoptosis-related genes but also changes the expression of autophagy-related genes. Additionally, overexpression of DAPK3 reduces the metabolic activity of cells. Conclusions: The overexpression of the DAPK3 gene can lead to cell death by both inducing apoptosis and autophagy pathways in the gastric adenocarcinoma cell line (MKN45). This anti-cancer activity may describe a hopeful strategy in the application of novel gene therapy for the treatment of gastric adenocarcinoma; however, further research is required to examine the clinical effectiveness of this strategy in GC treatment.


  • Open Access

    Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines

    by Ali Anjam-Najmedini, Rohollah Vahabpour, Ava Safaroghli-Azar, Alireza Kazemi, Parvaneh Movahhed, Majid Momeny, Davood Bashash

    Purpose: Although the complex structure of acute lymphoblastic leukemia (ALL) andinvolvement of diverse pathways in its pathogenesis have put an obstacle in the way of efficienttreatments, identification of strategies to manipulate the genome of neoplastic cells has madethe treatment prospective more optimistic.Methods: To evaluate whether the transduction of apoptin __a gene encoding a protein thatparticipates in the induction of apoptosis__ could reduce the survival of leukemic cells, wegenerated recombinant lentivirus expressing apoptin, and then, MTT assay, flow cytometricanalysis of DNA content, western blotting, and quantitative reverse transcription polymerasechain reaction (qRT-PCR) were applied.Results: Transduction of apoptin into different leukemic cells was coupled with the reductionin the viability and proliferative capacity of the cells. Among all tested cell lines, Nalm-6 andC8166 were more sensitive to the anti-leukemic property of apoptin. Moreover, we found thatthe transduction of apoptin in the indicated cell lines not only induced G2/M cell cycle arrestbut also induced apoptotic cell death by altering the balance between pro- and anti-apoptotictarget genes. The efficacy of apoptin transduction was not limited to these findings, as wereported for the first time that the overexpression of this gene could potentiate the anti-leukemicproperty of pan PI3K inhibitor BKM120.Conclusion: The results of this study showed that the transduction of apoptin into lymphoblasticleukemia cell lines induced cytotoxic effects and enhanced therapeutic value of PI3K inhibition;however, further investigations are demanded to ascertain the safety and the efficacy of apoptintransduction in patients with ALL.